Extrapyramidal Side Effects with Low Dose Amisulpride: A Report of Two Cases

Area of Science:

• Psychiatry
• Pharmacology
• Neuroscience

Background:

• Amisulpride is an atypical antipsychotic known for broad efficacy and a low incidence of extrapyramidal side effects (EPS).
• Its pharmacological profile suggests selective dopamine D2/D3 receptor blockade in limbic areas, sparing the striatum, which is thought to minimize EPS risk.

Observation:

• This report presents two distinct cases where patients experienced EPS.
• These adverse events were associated with lower doses of amisulpride than typically expected to cause such symptoms.

Findings:

• The occurrence of EPS at lower amisulpride doses challenges the established understanding of its safety profile.
• A potential mechanism for amisulpride-induced EPS, even at reduced dosages, is discussed within the report.

Implications:

• These findings suggest a need for closer monitoring of patients on amisulpride, even at lower therapeutic levels.
• Further research, particularly within the Indian population, is recommended to ascertain the true incidence of EPS and other side effects associated with amisulpride.